{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidddc62wwe5pbwvt4go652jev77s5z2vjcax5mg6arhglmzhlovzi",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mn55h75kas62"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibnbbiprl7qbpevztwmor5xrdayfe6ijfw6mlwgl3sagye5anfoby"
    },
    "mimeType": "image/jpeg",
    "size": 12221
  },
  "path": "/2026/05/30/kelun-biotech-presents-pivotal-phase-ii-data-for-lunbotinib-fumarate-a400-ep0031-in-ret-fusion-positive-nsclc-at-2026-asco/",
  "publishedAt": "2026-05-30T13:51:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "CHENGDU, China, May 30, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company’s next-generation selective RET inhibitor, lunbotinib fumarate (A400/EP0031, 宁泰莱®[1]), in advanced rearranged during transfection […]",
  "title": "Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO"
}